The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 170, Issue 2, Pages 236-246
Publisher
Wiley
Online
2015-03-30
DOI
10.1111/bjh.13381
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT
- (2014) G Visani et al. BONE MARROW TRANSPLANTATION
- Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)
- (2014) Emanuele Angelucci et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma
- (2013) C Piccoli et al. BRITISH JOURNAL OF PHARMACOLOGY
- Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation
- (2013) Hui-Ling Chen et al. CANCER LETTERS
- Short Communication Forced expression of OCT4 influences the expression of pluripotent genes in human mesenchymal stem cells and fibroblasts
- (2013) C.S. Palma et al. GENETICS AND MOLECULAR RESEARCH
- Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”
- (2013) Alfredo Molteni et al. LEUKEMIA RESEARCH
- The expression of Sox17 identifies and regulates haemogenic endothelium
- (2013) Raedun L. Clarke et al. NATURE CELL BIOLOGY
- Reviewing and Updating the Major Molecular Markers for Stem Cells
- (2013) Raquel Calloni et al. STEM CELLS AND DEVELOPMENT
- Role of SOX17 in hematopoietic development from human embryonic stem cells
- (2012) Y. Nakajima-Takagi et al. BLOOD
- Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
- (2012) Norbert Gattermann CURRENT PHARMACEUTICAL DESIGN
- Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox
- (2012) Shohei Kikuchi et al. FREE RADICAL BIOLOGY AND MEDICINE
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
- (2012) N. Gattermann et al. HAEMATOLOGICA
- Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome
- (2012) Alan F. List et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective toxicity towards myelodysplastic hematopoietic progenitors – Another rationale for iron chelation in MDS
- (2012) E. Fibach et al. LEUKEMIA RESEARCH
- Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors
- (2012) Vinod Pullarkat et al. LEUKEMIA RESEARCH
- Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes
- (2012) Julia Hartmann et al. LEUKEMIA RESEARCH
- Oct4 and Nanog Directly Regulate Dnmt1 to Maintain Self-Renewal and Undifferentiated State in Mesenchymal Stem Cells
- (2012) Chih-Chien Tsai et al. MOLECULAR CELL
- Reactive oxygen species: Are they important for haematopoiesis?
- (2011) José L. Sardina et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors
- (2011) S. He et al. GENES & DEVELOPMENT
- The effect of iron overload and chelation on erythroid differentiation
- (2011) Kazuki Taoka et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma
- (2011) Jin Lv et al. MEDICAL ONCOLOGY
- The Relationship Between Oxygen Concentration, Reactive Oxygen Species and the Biological Characteristics of Human Bone Marrow Hematopoietic Stem Cells
- (2011) Y. Hao et al. TRANSPLANTATION PROCEEDINGS
- Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
- (2010) E. Messa et al. HAEMATOLOGICA
- Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes
- (2010) H. Ghoti et al. HAEMATOLOGICA
- Empowering self-renewal and differentiation: the role of mitochondria in stem cells
- (2010) Jalees Rehman JOURNAL OF MOLECULAR MEDICINE-JMM
- Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
- (2010) Norbert Gattermann et al. LEUKEMIA RESEARCH
- Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review
- (2010) Roberto Guariglia et al. LEUKEMIA RESEARCH
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Regulation of Reactive Oxygen Species and Genomic Stability in Hematopoietic Stem Cells
- (2008) Kazuhito Naka et al. ANTIOXIDANTS & REDOX SIGNALING
- Stem cells and aging in the hematopoietic system
- (2008) Luigi A. Warren et al. MECHANISMS OF AGEING AND DEVELOPMENT
- Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal
- (2008) Leonard I. Zon NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started